By Agata Blaszczak-Boxe, Staff Writer
Published: 03/31/2014 08:54 PM EDT on LiveScience
Aspirin may help some people with colon cancer live longer, according to a new study.
Researchers looked at nearly 1,000 patients with colon cancer, and tracked them for between four and 10 years. They found 37.9 percent of those who regularly took aspirin died, compared with 48.5 percent of the patients who didn't take aspirin.
However, the benefit of taking aspirin was seen only in patients whose tumors made a certain protein, called HLA class I antigen. This protein may be involved in the immune system's response to cancer cells, the researchers said, although more research is needed to understand the mechanism.
"If our results are confirmed by others and aspirin is studied as a treatment in a proper phase three randomized trial, then we would have a valid new anti-cancer treatment that is both safe and cheap," said study author Gerrit Jan Liefers of Leiden University Medical Center in the Netherlands.
"In a world were new targeted therapies usually cost thousands of dollars and most have serious side effects, this would mean great progress," Liefers told Live Science. [Aspirin to Zoloft: The Scoop on 5 Medicines]
Colon cancer is the fourth most common cancer in the United States, but ranks second in number of yearly deaths (behind lung cancer). In 2013, about 143,000 people in the U.S. were diagnosed with colon cancer, and about 51,000 died from the disease, according to estimates from the National Cancer Institute.
In the study, the researchers analyzed tissue from tumors from 999 colon cancer patients who had undergone surgery between 2002 and 2008. Among the patients, 182 were aspirin users, and 69 of these patients died by January 2012. On the other hand, 396 of the 817 patients who didn't take aspirin died.
How aspirin may work to lengthen life in people with colon cancer is not clear, according to the researchers. For now, they speculate that aspirin may affect the ability of tumor cells circulating in the body to develop into new cancer growths, or metastases.
The study does not prove that people with colon cancer should start taking aspirin, Liefers said.
"We have to await the results of a randomized trial before we can recommend aspirin as a valid anti-cancer treatment," he said.
Dr. Alfred Neugut, an oncologist at Columbia University who was not involved in the study, agreed that treatments should not change based on the new findings.
However, in oncology, there is a tendency "to await randomized data before creating a new standard of care," Neugut wrote in an editorial accompanying the new study in the journal, wondering if this process should always be essential.
"For my own patients, I have so far not recommended aspirin [for colon cancer]. But I think based on current evidence, that if I personally had a stage III tumor, I would add aspirin to my treatment," Neugut wrote.
Previous research has found a link between aspirin use and a lower risk of developing colon cancer.
Follow Agata Blaszczak-Boxe on Twitter. Follow Live Science @livescience, Facebook & Google+. Original article on Live Science.
Copyright 2014 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. ]]>
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.